Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time Eisai Mar 10, 2025 19:24 HKT/SGT Read More
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan Eisai Mar 05, 2025 08:09 HKT/SGT Read More
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia Eisai Mar 04, 2025 16:22 HKT/SGT Read More
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" Eisai Mar 03, 2025 14:41 HKT/SGT Read More
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease Eisai Mar 03, 2025 12:53 HKT/SGT Read More
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone Eisai Feb 28, 2025 11:31 HKT/SGT Read More
エーザイ、線維芽細胞増殖因子受容体（FGFR）選択的チロシンキナーゼ阻害剤タスルグラチニブについて中国・香港・マカオ・台湾での開発・販売に関するライセンス契約をSciCloneと締結 Eisai Feb 28, 2025 10:00 JST Read More
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026 Soligenix, Inc Feb 22, 2025 03:50 HKT/SGT Read More
エーザイ、優れた人的資本経営・情報開示に取り組む企業として「人的資本リーダーズ 2024」「人的資本経営品質 ゴールド」に2年連続で選出 Eisai Feb 20, 2025 15:00 JST Read More
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease Eisai Feb 14, 2025 11:09 HKT/SGT Read More
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies Eisai Feb 03, 2025 16:23 HKT/SGT Read More
国立長寿医療研究センターとエーザイ、認知機能低下リスクの低減と栄養に関するガイダンス、および 宅配食/ミールキット開発の手引きを作成し、食品関連企業へ提供開始 Eisai Feb 03, 2025 10:40 JST Read More
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Eisai Jan 28, 2025 08:46 HKT/SGT Read More
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Eisai Jan 15, 2025 09:03 HKT/SGT Read More
エーザイとバイオジェン・インク、早期アルツハイマー病治療剤「レケンビ(R)」の皮下注射製剤維持投与に関する 生物製剤承認申請を米国FDAが受理 Eisai Jan 14, 2025 10:00 JST Read More
